Effects of omeprazole on plasma levels of raltegravir

Clin Infect Dis. 2009 Feb 15;48(4):489-92. doi: 10.1086/596503.

Abstract

Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH. Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / pharmacokinetics*
  • Anti-HIV Agents / therapeutic use
  • Drug Interactions*
  • Female
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / pharmacokinetics*
  • Omeprazole / therapeutic use
  • Plasma / chemistry*
  • Pyrrolidinones / pharmacokinetics*
  • Pyrrolidinones / therapeutic use
  • Raltegravir Potassium
  • Young Adult

Substances

  • Anti-HIV Agents
  • Pyrrolidinones
  • Raltegravir Potassium
  • Omeprazole